Cargando…

Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression

Triple-negative breast cancer (TNBC) is often treated with anthracyclines (e.g., epirubicin or doxorubicin), but very little is known about anthracycline resistance, especially epirubicin resistance in TNBC. To identify novel long noncoding RNAs (lncRNAs) involved in epirubicin resistance in TNBC, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengliang, Yang, Sujin, Lv, Mingming, Chen, Fei, Yin, Hong, Gao, Sheng, Tang, Jinhai, Yu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970185/
https://www.ncbi.nlm.nih.gov/pubmed/33747911
http://dx.doi.org/10.3389/fonc.2021.592215
_version_ 1783666385898962944
author Wang, Fengliang
Yang, Sujin
Lv, Mingming
Chen, Fei
Yin, Hong
Gao, Sheng
Tang, Jinhai
Yu, Jing
author_facet Wang, Fengliang
Yang, Sujin
Lv, Mingming
Chen, Fei
Yin, Hong
Gao, Sheng
Tang, Jinhai
Yu, Jing
author_sort Wang, Fengliang
collection PubMed
description Triple-negative breast cancer (TNBC) is often treated with anthracyclines (e.g., epirubicin or doxorubicin), but very little is known about anthracycline resistance, especially epirubicin resistance in TNBC. To identify novel long noncoding RNAs (lncRNAs) involved in epirubicin resistance in TNBC, we established a new TNBC MDA-MB-231 cell line that was resistant to epirubicin (Epi-R). A total of 12 differentially expressed lncRNAs were identified using RNA sequencing analysis of Epi-R cells. Among these lncRNAs, we found a novel intronic lncRNA, lnc005620, was highly expressed in Epi-R cells and human TNBC tissues. Further gain- and loss-of-function studies demonstrated that lnc005620 played an oncogenic role and partially abrogated the effects of epirubicin on TNBC cells. Using iTRAQ proteomics analysis, we found that three members of the integrin family, integrin β4, integrin β1 and integrin α6, were all upregulated in Epi-R MDA-MB-231 cells. Integrin β1, encoded by the ITGB1 gene, was validated to be a downstream target of lnc005620 in Epi-R MDA-MB-231 cells. Our study demonstrates that novel lnc005620 promotes TNBC progression and chemoresistance to epirubicin via integrin β1 both in vitro and in vivo and provides a promising therapeutic target for TNBC patients in terms of enhancing the benefits of epirubicin treatment.
format Online
Article
Text
id pubmed-7970185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79701852021-03-19 Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression Wang, Fengliang Yang, Sujin Lv, Mingming Chen, Fei Yin, Hong Gao, Sheng Tang, Jinhai Yu, Jing Front Oncol Oncology Triple-negative breast cancer (TNBC) is often treated with anthracyclines (e.g., epirubicin or doxorubicin), but very little is known about anthracycline resistance, especially epirubicin resistance in TNBC. To identify novel long noncoding RNAs (lncRNAs) involved in epirubicin resistance in TNBC, we established a new TNBC MDA-MB-231 cell line that was resistant to epirubicin (Epi-R). A total of 12 differentially expressed lncRNAs were identified using RNA sequencing analysis of Epi-R cells. Among these lncRNAs, we found a novel intronic lncRNA, lnc005620, was highly expressed in Epi-R cells and human TNBC tissues. Further gain- and loss-of-function studies demonstrated that lnc005620 played an oncogenic role and partially abrogated the effects of epirubicin on TNBC cells. Using iTRAQ proteomics analysis, we found that three members of the integrin family, integrin β4, integrin β1 and integrin α6, were all upregulated in Epi-R MDA-MB-231 cells. Integrin β1, encoded by the ITGB1 gene, was validated to be a downstream target of lnc005620 in Epi-R MDA-MB-231 cells. Our study demonstrates that novel lnc005620 promotes TNBC progression and chemoresistance to epirubicin via integrin β1 both in vitro and in vivo and provides a promising therapeutic target for TNBC patients in terms of enhancing the benefits of epirubicin treatment. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC7970185/ /pubmed/33747911 http://dx.doi.org/10.3389/fonc.2021.592215 Text en Copyright © 2021 Wang, Yang, Lv, Chen, Yin, Gao, Tang and Yu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Fengliang
Yang, Sujin
Lv, Mingming
Chen, Fei
Yin, Hong
Gao, Sheng
Tang, Jinhai
Yu, Jing
Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title_full Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title_fullStr Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title_full_unstemmed Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title_short Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
title_sort novel long noncoding rna 005620 induces epirubicin resistance in triple-negative breast cancer by regulating itgb1 expression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970185/
https://www.ncbi.nlm.nih.gov/pubmed/33747911
http://dx.doi.org/10.3389/fonc.2021.592215
work_keys_str_mv AT wangfengliang novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT yangsujin novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT lvmingming novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT chenfei novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT yinhong novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT gaosheng novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT tangjinhai novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression
AT yujing novellongnoncodingrna005620inducesepirubicinresistanceintriplenegativebreastcancerbyregulatingitgb1expression